> > >

Novo Nordisk Lab Program Form

This form will enable health care professionals and institutions to activate their Labcorp account and participate in the Novo Nordisk Lab Program. Email the completed form to fixsupport@labcorp.com.

Download

Preview

  • 0
  • 1

Additional Information

MixPro® Reconstitution Video

Register to get the latest updates about Esperoct®

Register to get the latest updates about Esperoct®

Register

Also available from Novo Nordisk:

NovoSeven® RT coagulation factor VIIa (recombinant) logo

Visit website
Prescribing Information

Rebinyn® coagulation Factor IX (recombinant) GlycoPEGylated logo

Visit website
Prescribing Information

Novoeight® antihemophilic factor (recombinant) logo

Visit website
Prescribing Information

Tretten® coagulation factor XIII a-subunit (recombinant) logo

Visit website
Prescribing Information

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information